Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for coronavirus in community care
ISRCTN33260034Phase 2Terminated
- Sponsor
- University of Oxford
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of adalimumab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by University of Oxford. Primary endpoint: Rate of progression to severe disease. Started Oct 2020; status: terminated.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN33260034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN33260034.